Ondine Biopharma Corporation is dedicated to the development of non-antibiotic anti-infective therapies for a broad spectrum of bacterial, viral and fungal infections. The Company is focused on the further development and commercialization of its patented light activated technology, Photodynamic Disinfection (PDD), for multiple applications. PDD provides antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. Ondine has launched is first PDD product Periowave™ for the treatment of chronic adult periodontitis (gum disease) in Canada. The Company is currently working towards the global expansion of Periowave™ into Europe and the US. In addition, Ondine is continuing to develop other applications of its PDD technology for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) as well as for other applications both within and outside of the oral cavity.
Ondine is a publicly-traded company listed on the Toronto and AIM stock exchanges under the symbol OBP. Ondine is headquartered in Vancouver, British Columbia, Canada, and has a research and development facility in Bothell, Washington, USA and an International office in St. Michael, Barbados.
| Ondine Biopharma Announces $1.78 Million Private Placement | 05/19/2009 - 07:00 | $1Million |
| Ondine Announces $400,000 Loan from Insider | 04/06/2009 - 07:00 | $0Million |
| Ondine Biopharma Announces $100,000 Private Placement Equity Financing | 02/23/2009 - 08:00 | $0Million |
| Ondine Biopharma Announces $400,000 Private Placement Equity Financing | 02/17/2009 - 08:00 | $0Million |
| Ondine Biopharma Announces $1 Million Private Placement Equity Financing | 01/23/2009 - 08:00 | $1Million |
| Ondine Announces Closing Of C$7.0 Million Private Placement Equity Financing | 12/07/2007 - 08:00 | $7Million |
| Ondine Biopharma Announces C$5.5 Million Private Placement Equity Financing | 11/22/2007 - 08:00 | $5Million |